Relay Therapeutics Hopes ‘Safety First’ Approach Will Pay Off For Targeted Breast Cancer Drug
Share Price Tanks After Virtually No Response To Therapy
Investors have deserted Relay after RLY-2608 failed to produce any clear response in breast cancer patients, but it maintains underlying data represent proof-of-concept for a more targeted and less toxic competitor to Novartis's Piqray.
